Last reviewed 2026-04-20 · How we verify

ALECTINIB

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Edema
• Constipation
• Nausea
• Diarrhea
• Vomiting
• Pneumonia
• Renal impairment
• Hyperbilirubinemia
• Increased AST
• Increased ALT
• Increased alkaline phosphatase

Key clinical trials

• Pharmacogenomics ANDA 221517 SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms (PHASE2, PHASE3)
• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (PHASE3)
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (PHASE2)
• Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 (PHASE1)
• A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
• Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (PHASE1, PHASE2)
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ALECTINIB CI brief — competitive landscape report
• ALECTINIB updates RSS · CI watch RSS